This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Jones, R. N. Articles by Sader, H. S. PubMed PubMed Citation Articles by Jones, R. N. Articles by Sader, H. S.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00294-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Antimicrobial Activity of DC-159a, a New Fluoroquinolone, Tested Against 1,149 Recent Clinical Isolates

JMI Laboratories, North Liberty, Iowa, USA; Tufts University School of Medicine, Boston, Massachusetts, USA; and Universidade Federal de Sao Paulo, Sao Paulo, Brazil

^* To whom correspondence should be addressed. Email: ronald-jones{at}jmilabs.com.

	Abstract

DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recent clinical isolates from five continents. Against pathogens associated with community-acquired respiratory infections (CA-RTI), the MIC₉₀ values (µg/ml) were: Streptococcus pneumoniae (0.12), Haemophilus influenzae (0.015-0.03), Moraxella catarrhalis (0.03) and -haemolytic streptococci (0.12). Similarly, DC-159a was potent against various types of staphylococci (MIC₉₀ range, 0.03-2 µg/ml), Enterococcus faecalis (MIC₉₀, 4 µg/ml), wildtype Enterobacteriaceae (MIC₉₀ range, 0.06-2 µg/ml), WILDTYPE Pseudomonas aeruginosa (MIC₉₀, 2 µg/ml) or Acinetobacter spp. (MIC₉₀, 0.12 µg/ml). Fluoroquinolone-non-susceptible (NS) organism subsets usually had elevated DC-159a MIC values, but MIC results were often two- to four-fold lower than levofloxacin or moxifloxacin. In conclusion, DC-159a appears to possess a balanced broad-spectrum of activity exceeding that of currently marketed fluoroquinolones, especially against CA-RTI pathogens.